Ligusticum

Other Names

Bear medicineBear rootCarum anthriscoidesChinese Lovage RootChuan XiongChuanxiongChuchupasteChuchupateChuchupatiChuchupatleChunkungCnidium officinaleColorado cough rootConioselinum anthriscoidesCortia striataEmpress of the dark forestGao BenGaobenGuariacaHierba del cochinoHuoGaoBenIndian parsleyIndian rootLiaoGaoBenLicorice rootLigustici Rhizoma et RadixLigusticum chuanxiongLigusticum chuanxiong Hort.Ligusticum jeholenseLigusticum officinaleLigusticum porteriLigusticum scoticumLigusticum sinenseLigusticum striatumLigusticum wallichiiLovageLovage rootLoverootMountain carrotMountain ginsengMountain lovageNipoOreocome striataOsháOshaOsha rootPorter's licorice rootPorter's ligusticumPorter's lovagePorter's wild lovageRaíz del cochinoRhizoma ChuanxiongRhizoma LigusticiSelinum striatumSichuan lovageSichuan lovage rootSouthern ligusticumStraw WeedSzechwan lovageUmbelliferae (family reference)WashíWild celeryWild lovageWild parsleyWild parsnipXiongqiongYerba de cochino川芎藁本

Synopsis

Ligusticum: A Comprehensive Reference

1. Identity and Botanical Classification

Genus and Key Medicinal Species

Ligusticum is a genus of approximately 60 species of flowering plants in the family Apiaceae (Umbelliferae), native to cool temperate regions of the Northern Hemisphere. Its name is believed to derive from the Italian region of Liguria. While the genus is large, a small number of species account for the overwhelming majority of traditional and scientific interest. The genus Ligusticum, consisting of approximately 50 species growing in Asia, Europe, and North America, is complex and widespread.

The two most pharmacologically studied and commercially prominent species are:

Ligusticum chuanxiong Hort. (syn. Conioselinum anthriscoides; formerly called Ligusticum wallichii Franch.): The dried rhizome of Ligusticum chuanxiong S.H.Qiu, Y.Q.Zeng, K.Y.Pan, Y.C.Tang and J.M.Xu (Apiaceae; including the horticultural variety Ligusticum chuanxiong Hort.) — synonym: Conioselinum anthriscoides (H.Boissieu) Pimenov and Kljuykov (the taxonomic classification adopted by the World Checklist of Vascular Plants) — is a traditional Chinese botanical drug renowned for its anti-inflammatory and antioxidant properties. It is one of the 50 fundamental herbs used in Chinese herbology, where it is called chuānxiōng (川芎); in English, Szechwan lovage.
Ligusticum sinense Oliv. and L. jeholense Nakai et Kitag.: Ligusticum sinense Oliv. and L. jeholense Nakai et Kitag. are globally recognized as medicinal botanical species, specifically the rhizomes and roots. These plant parts are collectively referred to as Ligustici Rhizoma et Radix (LReR), which is recorded in the Pharmacopoeia of the People's Republic of China (Ch. P). LReR enjoys widespread recognition in many countries such as China, Russia, Vietnam, and Korea. It is an herbal remedy traditionally employed for dispelling wind and cold, eliminating dampness, and alleviating pain.
Ligusticum porteri J.M.Coult. & Rose (Osha): L. porteri (osha) is used in Western herbal medicine. The root of Ligusticum porteri, known as Oshá, has long been esteemed — particularly among Native Americans and Hispanic populations in the Southwest and Mexico — as a traditional remedy for colds, sore throat, and other ailments.

Botanical Parts Used and Common Preparations

Ligusticum chuanxiong Hort. (LC), family Umbelliferae, is also called Ligusticum wallichii Franchat. It is mainly distributed in Sichuan province (China) and first recorded in the Divine Husbandman's Classic of the Materia Medica (Shen Nong Ben Cao Jing). The rhizome is the principal plant part used across all three major medicinal species. Conioselinum anthriscoides (H. Boissieu) Pimenov & Kljuykov, also known as Ligusticum chuanxiong Hort., is a perennial Umbelliferae herb, whose dried rhizome is commonly called Chuanxiong Rhizoma. Chuanxiong Rhizoma is widely used in TCM, especially for cardiocerebrovascular and gynecological diseases.

Common preparation forms encountered in clinical and traditional settings include:

Dried whole or sliced rhizome (decoction-ready form), used in multi-herb TCM formulas
Standardized water or ethanol extracts in tablet, capsule, or granule form
Essential oil preparations, used topically or via nasal inhalation
Isolated alkaloid preparations, most notably tetramethylpyrazine (TMP) hydrochloride for parenteral clinical use in China

In China, the most commonly used ligustrazine preparation is TMP hydrochloride. CX can be administered alone or in combination with other traditional Chinese medicines (TCMs) or chemical drugs.

2. Traditional and Historical Use

Traditional Chinese Medicine (TCM)

Ligusticum chuanxiong, commonly known as Chuanxiong, is a traditional Chinese medicinal herb that has been utilized for over 2,000 years, particularly for its benefits in promoting blood circulation and alleviating various ailments. This herb is derived from the rhizome of the plant. The rhizome of LC is warm in property and pungent in flavor, with functions of promoting the circulation of the blood and qi, expelling wind, and alleviating pain, which has high medicinal value. LC has long been used as a traditional Chinese medicine in folk remedies and is widely applied in food preparation as a health protection.

The rhizome of Ligusticum chuanxiong Hort. (Chuanxiong) originated from the Divine Husbandman's Classic of the Materia Medica (Shen Nong Ben Cao Jing), and is a well-known TCM herb. Based on the literature review, Chuanxiong formulae are the most common Chinese classical and/or patent prescriptions for treating headache, both in ancient and modern times.

Within the TCM conceptual framework, the herb holds a specific classification and set of functions: CX facilitates blood circulation (huō xuě tōng luò), dispels wind-cold (qū fēng sǎn hán). Chuanxiong Rhizoma is widely used in TCM, especially for cardiocerebrovascular and gynecological diseases. In classical TCM dysmenorrhea prescriptions, Ligusticum chuanxiong Hort (Chuan Qiong) ranked as one of the seven core medicinal materials in prescriptions for dysmenorrhea, alongside Angelica sinensis, Rehmannia glutinosa, and Paeonia lactiflora.

Korean and East Asian Folk Medicine

The root and rhizoma of Ligusticum species are generally used in traditional medicine in China, Japan, and Korea to treat headaches, arthralgia, pain, common cold, and cardiovascular disease such as angina pectoris. LReR enjoys widespread recognition in many countries such as China, Russia, Vietnam, and Korea.

Native American and Hispanic Traditional Medicine (Ligusticum porteri — Osha)

The root of Ligusticum porteri, known as Oshá, has long been esteemed — particularly among Native Americans and Hispanic populations in the Southwest and Mexico — as a traditional remedy for colds, sore throat, and other ailments. Ligusticum porteri is distributed throughout the Rocky Mountain range, spanning Montana and Wyoming in the north, through Colorado, Nevada, and Utah, to New Mexico, Arizona, and Mexico.

Historically, tribes including the Chiricahua, Mescalero, and White Mountain bands of the Apache, Navajo, Zuni and other Pueblos, Southern Ute, Lakota, and the Tarahumara in Mexico used oshá to treat ailments such as the conditions listed above and others. Fifteen tribes are documented using oshá, and those uses are practiced today; more tribes likely use oshá, especially in and near the range of the plant. Apache, Navajo, and Zuni tribes prized osha root for respiratory support, using it to address coughs, colds, sore throats, and pneumonia. The root was chewed during healing ceremonies, made into teas for digestive complaints, or applied topically for wounds and snake bites.

American Ligusticum species have been used as anticonvulsants, to stimulate appetite, and to treat anemia, hemorrhage, tuberculosis, stomach disorders, heart troubles, respiratory infections, earaches, sinus infection, and congestion, and other ailments (Moerman 1998). Oshá is commonly referred to as bear root by Native American tribes because bears have been observed using and interacting with the root.

Native to high altitudes in the Southwest and Rocky Mountain states, the root of the osha plant (Ligusticum porteri) is a traditional indigenous American remedy for respiratory infections and digestive problems. A related plant, L. wallichii, has a long history of use in Chinese medicine, and most of the scientific studies on osha were actually performed on this species.

3. Key Phytochemical Constituents

Over 100 metabolites have been isolated and identified from L. chuanxiong, classified into nine major classes. Key bioactive compounds include senkyunolide A, ligustilide, tetramethylpyrazine (TMP), and Ligusticum CX polysaccharides (LCP). The published chemical literature identifies three dominant structural categories that account for most of the observed pharmacological activity.

Phthalide Lactones

Several phthalide metabolites have been identified and isolated, which can be categorized into three main types based on their core structures: monomeric phthalides, hydroxylated phthalides, and dimeric phthalides. Representative metabolites include cnidilide, senkyunolide A, and ligustilide. The major constituent is Z-ligustilide (61–69% in the essential oil), with other phthalides such as E-ligustilide, Z-butylidenephthalide, 3-butylphthalide, 3-butylidene-4-hydroxyphthalide, senkyunolide A, 6,7-epoxyligustilide, senkyunolide F, senkyunolide H, senkyunolide I, 6,7-dihydroxyligustilide, and phthalide dimers including riligustilide, levistolide A, and senkyunolide O. Previous studies have demonstrated the efficacy of phthalides in improving blood circulation, reducing blood stasis, and providing progressive stimulation, particularly for cardiovascular and cerebrovascular diseases, as well as dysmenorrhea.

Alkaloids: Tetramethylpyrazine (TMP / Ligustrazine)

Tetramethylpyrazine (TMP), an alkaloid extracted from CX, is one of the active components of CX. In recent decades, TMP has been used to treat various diseases, especially cardiovascular diseases, and has achieved good therapeutic results. Many studies have confirmed that TMP has a variety of pharmacological effects, including anti-myocardial ischemia, anti-cerebral ischemia, anti-hypertension, anti-atherosclerosis, anti-cancer, anti-oxidation, anti-inflammation, and anti-apoptosis. TMP is a natural compound isolated from Chinese herbal medicine Ligusticum wallichii (Chuan Xiong), which has been extensively used for medicinal purposes for more than 2,000 years. TMP was first isolated in 1957 and has been increasingly studied for its action on myocardial and cerebral infarction since the 1970s.

Phenolic Acids: Ferulic Acid

Phenolic compounds (ferulic acid), phthalides (ligustilide), and alkaloid compounds (ligustrazine) are the three main groups of constituents. Ligustrazine, ferulic acid, and ligustilide are the main active constituents of Ligusticum chuanxiong, especially in the treatment of neurovascular and cardiovascular diseases. Ferulic acid is stated to possess numerous bioactivities mostly associated with its antioxidant and radical scavenging activities.

Polysaccharides and Other Compounds

Ligusticum CX polysaccharides (LCPs) are another active metabolite of CX with multiple bioactivities, including antioxidant, immunomodulatory, antitumor, and antibacterial effects. In addition to these metabolites, CX also contains aldehydes, phenols, ketones, anhydrides, and aromatic hydrocarbons. Ligustici Rhizoma et Radix (LReR) has been subjected to comprehensive chemical analysis, resulting in the identification and isolation of 190 compounds, including phthalides, phenylpropanoids, flavonoids, phenolic acids, triterpenes, steroids, volatile oil, fatty acids, and other constituents.

4. Mechanisms of Action

Cardiovascular and Antiplatelet Mechanisms

CX demonstrates significant pharmacological effects in treating cardiocerebrovascular diseases (CCVDs), such as atherosclerosis, myocardial and cerebral ischemia-reperfusion injury, and hypertension. Its therapeutic mechanisms include antiplatelet activity, endothelial cell protection, anti-inflammatory, antioxidant, and anti-apoptotic properties.

TMP is reported to protect ischemia-reperfusion injury of heart, brain, and kidney via reducing oxidative stress, attenuating Ca²⁺ overload, inhibiting apoptosis, and inhibiting inflammatory reaction. It is also demonstrated that TMP can inhibit platelet aggregation, depress blood viscosity, and ameliorate microcirculation, which could be another important mechanism to treat cardiovascular and cerebrovascular diseases.

Emerging experimental studies and clinical trials have demonstrated that TMP prevents atherosclerosis as well as ischemia-reperfusion injury. The cardioprotective effects of TMP are mainly related to its antioxidant, anti-inflammatory, or calcium-homeostasis effects. Bioassay methods have been put forward to evaluate the pharmaceutical activities of Szechwan lovage rhizome (SLR) to improve hemorheology, hemodynamics, and vascular microcirculation, as well as its anti-platelet aggregation and anticoagulation properties.

Anti-inflammatory Mechanisms

Chinese Ligusticum root contains alkaloids that have been shown in studies to inhibit TNF-alpha production and TNF-alpha-mediated NF-κB activation. One study conducted in Japan showed the active compounds found in Ligusticum sinense have both anti-inflammatory and pain-reducing effects, exerting its anti-inflammatory benefits in the early and the late stages of processes in the inflammatory pathology.

The alkaloid TMP exerts its anti-inflammatory effect particularly through multiple signaling pathways. Research on cardiovascular effects has reviewed evidence covering: protecting mitochondria and improving energy metabolism, scavenging oxygen free radicals (OFRs) to inhibit lipid peroxidation, attenuating calcium (Ca²⁺) overload and maintaining Ca²⁺ homeostasis in cells, inhibiting apoptosis and protecting myocardial cells, interfering with the inflammatory reaction and mitigating cell injury, interfering with cell signaling pathways, and improving function of endothelial cells.

Neuroprotective Mechanisms

Traditional Chinese herb Ligusticum chuanxiong Hort is widely used for the treatment of stroke and cardiovascular diseases due to its proven clinical benefits. Many bioactive components of this herb have been identified, of which tetramethylpyrazine (TMP) is recognized as a prominent bioactive ingredient and has been widely used as a possible intervention against ischemic brain injury.

Vasorelaxant Mechanisms

Major chemical components, including essential oil, alkaloids, phenolic acids, and phthalide lactones, display vasorelaxation, anti-inflammation, antioxidant, antiproliferation, and other activities in both in vitro and in vivo studies. Research on L. jeholense demonstrated endothelium-independent vasorelaxant effects in rat thoracic aorta models.

Antifungal Mechanisms

To evaluate the antimicrobial effects of metabolites of Ligusticum chuanxiong (CX), one study systematically studied the antimicrobial activity of extracts of CX. The results of toxicity measurement showed that the extracts of CX had good biological activities against Botrytis cinerea, Sclerotinia sclerotiorum, Alternaria alternata, and Pythium aphanidermatum. The antifungal active components of CX were identified as Senkyunolide A and Ligustilide by mass spectrometry and nuclear magnetic resonance.

5. Scientific Evidence by Area of Use

5.1 Cardiovascular and Cerebrovascular Disease

Tetramethylpyrazine (TMP), a pharmacologically active component isolated from the rhizome of the Chinese herb Rhizoma Chuanxiong, has been clinically used in China and Southeast Asian countries for the prevention and treatment of cardiovascular diseases (CVDs) for about fifty years. The pharmacological effects of TMP on the cardiovascular system have attracted great interest. Emerging experimental studies and clinical trials have demonstrated that TMP prevents atherosclerosis as well as ischemia-reperfusion injury.

Tetramethylpyrazine, a natural compound from Ligusticum wallichii (Chuan Xiong), has been extensively used in China for cardiovascular and cerebrovascular diseases for about 40 years. Because of its effectiveness in multisystems, especially cardiovascular, its pharmacological action, clinical application, and structural modification have attracted broad attention.

CX contains tetramethylpyrazine, Z-ligustilide, ferulic acid, and other components, which are widely used in CVDs, including hypertension, coronary heart disease, atherosclerosis, heart failure, cerebral ischemia, and cerebral hemorrhage.

Evidence characterization: Cardiovascular effects of tetramethylpyrazine, including protecting mitochondria, scavenging oxygen free radicals, attenuating calcium overload, and inhibiting apoptosis, have been reviewed in the literature. However, further rigorously designed randomized controlled trials are warranted. Most direct human clinical evidence for TMP involves Chinese clinical practice settings, which limits generalizability to broader international populations. The phthalides, organic acids, and alkaloids of Ligusticum species have emerged as a good source of traditional medicines for the management of cardio- and cerebrovascular conditions, inflammation, and neurodegenerative disorders. The species have demonstrated wide pharmacological actions and have great potential to yield multipotent drugs if challenges such as poor bioavailability, solubility, and toxicological profiles are addressed.

5.2 Migraine and Headache

Chuanxiong-containing formulae represent one of the more rigorously studied clinical applications of the genus. A systematic review and meta-analysis aimed to assess the current available evidence of herbal Chuanxiong (Ligusticum chuanxiong Hort. root) formulae for the treatment of migraine according to high-quality randomized controlled trials (RCTs). English and Chinese electronic databases were searched from their inceptions until March 2017. The methodological quality of included studies was assessed by the Cochrane Collaboration risk of bias tool, and RCTs with Cochrane risk of bias (RoB) score ≥4 were included in the analyses. Nineteen RCTs with 1,832 participants were identified. The findings indicated that Chuanxiong formulae exerted symptom relief for migraine.

A more recent high-quality trial investigated a specific Chuanxiong preparation: A randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of Chuanxiong Qingnao Granule (CQG) to treat migraine. All migraineurs were recruited and randomly assigned into a treatment group treated with CQG and a control group treated with a placebo. The whole research process included a 4-week baseline, 12-week intervention, and 12-week follow-up. A total of 346 migraineurs completed the research and were included in the intention-to-treat analyses. The response rates differed significantly between the treatment group and the control group (71.5% vs. 12.1% at week 12 and 83.1% vs. 3.4% at week 24). Attack frequency, days of headache attack, VAS, FSS, HAMD, and MIDAS decreased at week 12 in both groups with more reduction in the treatment group (P < 0.001). No severe adverse events were observed in this trial.

Evidence characterization: While the migraine evidence base is larger than for most TCM herbs, it is important to note that virtually all trials use multi-herb formulae in which Chuanxiong is one component, making it impossible to isolate the contribution of Ligusticum alone. Previous systematic reviews of TCM for migraine were prevented from making firm conclusions because of poor methodology. The included RCT evidence is predominantly from Chinese centers, with heterogeneous comparators and outcome measures.

5.3 Neuroprotection and Ischemic Stroke

The compound 2,3,5,6-tetramethylpyrazine (TMP) is one of the most important active ingredients isolated from Chuan Xiong. Over the past two decades, TMP has been demonstrated, in both animal experiments and clinical practice, to alleviate ischemic brain injury.

TMP was first isolated in 1957 and has been increasingly studied for its action on myocardial and cerebral infarction since the 1970s. In the past decades, researchers explored other pharmacological capabilities of TMP in various diseases, such as coronary heart disease, diabetes, and cancers.

Evidence characterization: The majority of neuroprotection data derive from animal models (rodent middle cerebral artery occlusion models, in vitro cell lines). Clinical trials of TMP in acute ischemic stroke have been conducted primarily in China, often as adjunctive therapy to standard care. Published systematic data characterize this as a promising area requiring large, independently conducted, rigorously designed RCTs to confirm benefit.

5.4 Gynecological Conditions and Dysmenorrhea

Ligusticum chuanxiong has been used to treat dysmenorrhea. In traditional Chinese medicine, Ligusticum Chuan Xiong has been utilized to address menstrual disorders such as irregular periods, dysmenorrhea (painful menstruation), and menstrual cramps. Studies have indicated that its bioactive compounds may exert regulatory effects on uterine contractions and inflammatory pathways, offering insights into how it may modulate menstrual symptoms.

Chuanxiong Rhizoma has the functions of promoting blood circulation, removing blood stasis, antibacterial, antiviral, and calming the mind to promote sleep. It is used to treat cardiocerebrovascular and gynecological diseases, neurodegenerative disease, psoriasis.

Evidence characterization: Use for dysmenorrhea and broader gynecological applications is supported largely by traditional practice, animal model data, and a small number of clinical observations. Robust human RCT data specifically targeting dysmenorrhea in isolation from other herbs are limited in the peer-reviewed English-language literature.

5.5 Anti-inflammatory and Analgesic Applications

Recent studies have shown that medicinal Ligusticum plants have anti-infective, sedative, analgesic, anti-cancer, anti-inflammatory, anti-mycobacterial, anti-nociceptive activity, anti-neuroinflammatory, and vasorelaxation effects. The pharmacological activities have been explored through modern in vivo and in vitro studies, confirming anti-inflammatory, analgesic, and anti-melanin effects.

Evidence characterization: Anti-inflammatory and analgesic effects are primarily demonstrated in in vitro cell assays and rodent models. Extrapolation to human therapeutic dosing is not established in well-controlled human trials. Evidence remains at the preclinical stage for these specific endpoints.

5.6 Respiratory Conditions (Osha / L. porteri)

Oshá (Ligusticum porteri), found growing at high elevation sites in the southwestern United States and northwestern Mexico, is a medicinal plant whose roots are being sold by herbal product companies to treat influenza, bronchitis, coughs, colds, and sore throat. Hispanics and Native Americans have used Ligusticum porteri preparations for many years for the treatment of many diseases. L. porteri enhances the immune system, stimulates appetite, and improves gastrointestinal discomforts such as indigestion and stomach upset associated with vomiting.

Research identifies Z-ligustilide as osha's primary active compound, showing significant antioxidant, anti-inflammatory, and antimicrobial effects in laboratory studies.

Evidence characterization: Some people use osha for respiratory tract infections, skin infections, and viral infections such as herpes and HIV/AIDS. But there is no good scientific evidence to support these uses. Ligusticum porteri roots have been traditionally used in folk medicine, but the scientific basis is unclear. As of available peer-reviewed literature, clinical trials specifically on L. porteri for respiratory indications in humans are absent.

5.7 Antifungal Activity

Laboratory studies have documented antifungal properties of L. chuanxiong extracts. The extracts of CX had good biological activities against Botrytis cinerea, Sclerotinia sclerotiorum, Alternaria alternata, and Pythium aphanidermatum. Under the concentration of 1,000 mg/L, the control effect of CX extract on Blumeria graminis was more than 40%, and the control effect on Botrytis cinerea was 100%. The antifungal active components of CX were identified as Senkyunolide A and Ligustilide.

Evidence characterization: These are laboratory (in vitro) and limited in vivo plant-pathogen studies. No human clinical trials of Ligusticum extracts for antifungal indications have been identified in the peer-reviewed literature.

6. Body Systems and Health Areas Associated with Ligusticum

CX can be administered alone or in combination with other traditional Chinese medicines (TCMs) or chemical drugs, showing efficacy in cardiovascular, nervous system, digestive system disorders, as well as analgesia and anticancer activities. The following body systems are those with the most published evidence, traditional documentation, or both:

Cardiovascular system: Atherosclerosis, hypertension, coronary heart disease, myocardial ischemia, platelet aggregation, microcirculation
Cerebrovascular / nervous system: Ischemic stroke, neurodegeneration, migraine, neuropathic pain
Female reproductive system: Dysmenorrhea, menstrual irregularity, gynecological blood stasis conditions
Respiratory system: Especially via L. porteri (osha) for colds, coughs, upper respiratory infection
Musculoskeletal system: Arthralgia, neck and shoulder pain
Integumentary system: Anti-melanin effects (documented for L. sinense/L. jeholense), psoriasis
Immune and antimicrobial: Antifungal, antibacterial, and antiviral properties documented in vitro

7. Dosage Forms and Reported Dosages

Dosage information in the published literature reflects a range of preparation types and clinical contexts. The following are drawn directly from study reports:

Chuanxiong Qingnao Granule (CQG) in the migraine RCT: This study was a randomized, double-blind, placebo-controlled trial. All migraineurs were recruited and randomly assigned into a treatment group treated with CQG and a control group treated with a placebo. The whole research process included a 4-week baseline, 12-week intervention, and 12-week follow-up. (Specific gram dosing per dose for CQG is not reported in the available abstract data.)
Animal toxicology reference dose (lipid study): The oral administration of Ligusticum chuanxiong at an equivalent dosage of 30 times that given to patients for 90 days significantly lowered serum total cholesterol (TC) and triglyceride (TG) levels.
TMP hydrochloride: In China, the most commonly used ligustrazine preparation is TMP hydrochloride, typically used parenterally in Chinese clinical settings for cardiovascular and cerebrovascular indications. Specific IV or oral dosing parameters are reported in Chinese-language clinical literature reviewed by the PMC 2016 cardiovascular actions review but exact mg-per-dose figures are not consistently described in English-language abstracts.
Essential oil — administration route comparison: The essential oil (EO) from LC is demonstrated to have faster onset of action as well as better analgesic and sedative efficacy after nasal administration than oral administration.
Pharmacokinetics of ligustilide: The pharmacokinetics of ligustilide in humans are little understood, but animal studies have found that after oral administration, less than 3% of ligustilide was absorbed at only the highest dose (500 mg/kg) and was rapidly eliminated. The main metabolic reactions of phthalides appear to be conjugation with glutathione, cysteine, glucuronic, and sulfuric acids.

Standardized commercial extracts are noted to be produced to target specific constituent levels: Premium ligusticum products are often standardized to contain consistent levels of key bioactives — for example, a minimum percentage of ferulic acid (typically 0.5–1.5%) or total phthalides.

8. Safety Considerations and Interactions

Anticoagulant and Antiplatelet Activity

The anticoagulant properties of Ligusticum constituents, particularly ferulic acid and TMP, are pharmacologically well documented and represent a clinically relevant safety concern when the herb is used alongside pharmaceutical anticoagulants or antiplatelet agents. The anticoagulant ability of ferulic acid and its applications for improving blood compatibility have been reported in the biomaterials literature. Bioassay methods have been developed to evaluate the pharmaceutical activities of Szechwan lovage rhizome to improve hemorheology, hemodynamics, and vascular microcirculation, as well as its anti-platelet aggregation and anticoagulation properties.

Pregnancy and Lactation

Ligusticum porteri was occasionally used in very large amounts by Spanish New Mexicans as an abortifacient or emmenagogue. However, researchers George A. Conway and John C. Slocumb were unable to locate any person who reported successful use of this plant for this purpose. The American Herbal Products Association Safety & Labeling Guidelines Subcommittee recommended in 1997 that it should be labeled as not to be used during pregnancy.

For the broader genus, stimulant effects on uterine smooth muscle — attributed in part to ligustilide and phthalide components — are noted in experimental literature. The uterine relaxant and contractile activity of isoindolines and phthalides from the rhizomes of L. chuanxiong has been specifically studied, underscoring that the herb may affect uterine contractility in ways that are relevant to pregnancy safety.

Bioavailability and Metabolic Limitations

The pharmacokinetics of ligustilide in humans are little understood, but animal studies have found that after oral administration, less than 3% of ligustilide was absorbed at only the highest dose (500 mg/kg) and was rapidly eliminated. This extremely poor oral bioavailability of ligustilide, a primary phthalide constituent, represents a significant pharmacological challenge, as it means that the concentrations reached in humans from oral preparations may differ substantially from those that produce effects in laboratory studies.

Species and Product Identification

Evaluating and controlling the quality of TCMs are crucial issues in their modernization research. The accurate identification of the active constituents in Chinese medicine is essential, as their substitution with similar or unrelated species can impact the medicine's efficacy. For osha specifically, care must be taken not to confuse osha with poisonous hemlock. The leaves of the two plants are very similar.

Sustainability and Wild-Harvest Concerns (Osha)

Osha is primarily wild collected for the herbal supplement market. This is reducing populations of this plant throughout its range. If harvest continues at current levels, the plant is in danger of becoming locally extinct in some areas. In 1999, NatureServe evaluated the species as vulnerable (G3) at the global level.

General Bioavailability and Formulation Challenges

The species have demonstrated wide pharmacological actions and have great potential to yield multipotent drugs if challenges such as poor bioavailability, solubility, and toxicological profiles are addressed. These structural and pharmacokinetic limitations are significant in interpreting the clinical evidence and in predicting therapeutic outcomes from commercial supplement products.

References

Health Conditions

Health conditions that Ligusticum may help support.

No conditions available.

Body Systems

Body systems that Ligusticum may help support.

No body systems available.